These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22711062)

  • 1. Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis.
    Croze E; Yamaguchi KD; Knappertz V; Reder AT; Salamon H
    Pharmacogenomics J; 2013 Oct; 13(5):443-51. PubMed ID: 22711062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in the treatment of multiple sclerosis?
    Weinstock-Guttman B; Jacobs LD
    Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term experience with interferon beta-1b (Betaferon)in multiple sclerosis.
    Arnason BG
    J Neurol; 2005 Sep; 252 Suppl 3():iii28-iii33. PubMed ID: 16170497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.
    Johnston J; So TY
    Drugs; 2012 Jun; 72(9):1195-211. PubMed ID: 22642799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Eur J Neurol; 2001 Mar; 8(2):141-8. PubMed ID: 11284992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. History of modern multiple sclerosis therapy.
    Lublin F
    J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment and dose optimisation BENEFIT and BEYOND.
    Hartung HP
    J Neurol; 2005 Sep; 252 Suppl 3():iii44-iii50. PubMed ID: 16170501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
    Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
    Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.
    Pan F; Goh JW; Cutter G; Su W; Pleimes D; Wang C
    Clin Ther; 2012 Sep; 34(9):1966-76. PubMed ID: 22906738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
    Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
    J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis (INCOMIN Trial) II: analysis of MRI responses to treatment and correlation with Nab.
    Barbero P; Bergui M; Versino E; Ricci A; Zhong JJ; Ferrero B; Clerico M; Pipieri A; Verdun E; Giordano L; Durelli L;
    Mult Scler; 2006 Feb; 12(1):72-6. PubMed ID: 16459722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.
    Khan OA; Tselis AC; Kamholz JA; Garbern JY; Lewis RA; Lisak RP
    Mult Scler; 2001 Dec; 7(6):349-53. PubMed ID: 11795454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients.
    Pachner AR; Narayan K; Pak E
    Neurology; 2006 Feb; 66(3):444-6. PubMed ID: 16476953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
    Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
    Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving compliance with interferon-beta therapy in patients with multiple sclerosis.
    Portaccio E; Amato MP
    CNS Drugs; 2009; 23(6):453-62. PubMed ID: 19480465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of a 'refrigeration-free' formulation of interferon beta-1b--results of a double-blind, multicentre, comparative study in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Baum K;
    J Int Med Res; 2006; 34(1):1-12. PubMed ID: 16604818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.
    Pachner AR; Dail D; Pak E; Narayan K
    J Neuroimmunol; 2005 Sep; 166(1-2):180-8. PubMed ID: 16005084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study.
    Cadavid D; Wolansky LJ; Skurnick J; Lincoln J; Cheriyan J; Szczepanowski K; Kamin SS; Pachner AR; Halper J; Cook SD
    Neurology; 2009 Jun; 72(23):1976-83. PubMed ID: 19279320
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose steroids reduce flu-like symptoms at the initiation of IFNbeta-1b in relapsing-remitting MS.
    Río J; Nos C; Marzo ME; Tintoré M; Montalban X
    Neurology; 1998 Jun; 50(6):1910-2. PubMed ID: 9633761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.